🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Benjamin Powers

University of Kansas

ORCID: 0000-0002-9406-8916

Also affiliated with The University of Kansas Health System, The University of Kansas Cancer Center, University of Kansas Medical Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Bringing experimental therapeutics clinical trials network (ETCTN) to underrepresented population.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6542
Top 100%
0DataRank
Top 100%0 citations

Gary C. Doolittle, Rahul Atul Parikh, Anup Kasi, Elizabeth Wulff‐Burchfield, Benjamin Powers +15 more

Papers

Driven by 10 papers — median percentile 0. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437
N/A
6.5DataRank · unranked
846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002990
N/A
4.8DataRank · unranked
160 citations

Megan Othus, Sandip Pravin Patel, Chris Ryan, Ashish Sangal, Benjamin Powers +15 more

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial

The Lancet(2024)10.1016/s0140-6736(24)01812-9
N/A
1.4DataRank · unranked
84 citations

Karla V. Ballman, Angela Hong, Scott M. Schuetze, Andrew J. Wagner, Varun Monga +23 more

SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer

Cancer(2024)10.1002/cncr.35243
N/A
0.496DataRank · unranked
15 citations

Elizabeth Guadarrama, Young Kwang Chae, Michael J. Dennis, Benjamin Powers, Chih‐Yi Liao +9 more

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009128
N/A
0.380DataRank · unranked
9 citations

Megan Othus, Sandip Pravin Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan +11 more

Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma

npj Precision Oncology(2025)10.1038/s41698-024-00798-1
N/A
0.303DataRank · unranked
5 citations

Eleanor Cano-Linson, Young Kwang Chae, Shiruyeh Schokrpur, Christopher D. Lao, Benjamin Powers +13 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11516
N/A
0DataRank · unranked
0 citations

Megan Othus, Sandip Pravin Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan +10 more

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11531
N/A
0DataRank · unranked
1 citations

Shing M. Lee, Liner Ge, Mihaela Druta, Anthony P. Conley, Mary Louise Keohan +14 more

Bringing experimental therapeutics clinical trials network (ETCTN) to underrepresented population.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6542
Top 100%
0DataRank
Top 100%0 citations

Gary C. Doolittle, Rahul Atul Parikh, Anup Kasi, Elizabeth Wulff‐Burchfield, Benjamin Powers +15 more

A phase 2 study of belinostat and SGI-110 (guadecitabine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps11578
N/A
0DataRank · unranked
6 citations

Shing Mirn Lee, Mia C. Weiss, Brittany L. Siontis, Benjamin Powers, Warren Chow +6 more